2025-09-10
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for treating type 2 diabetes (Mounjaro) and obesity (Zepbound). Administered weekly via injection, it demonstrates high efficacy in lowering A1C and promoting substantial weight loss by reducing appetite and food intake, with gastrointestinal events being the most reported adverse reactions.【详细】
